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Location, Location, Location:
Compartmentalization of Early
Events in Leukotriene
Biosynthesis*

this minireview on the early events in the LT biosynthetic pathway, specifically a major branch point in LT biosynthesis that
determines whether cysteinyl-LTs that result from the pathway
that requires conjugation with glutathione are produced or
whether the non-cysteinyl-LT LTB4 is synthesized.

Published, JBC Papers in Press, May 27, 2010, DOI 10.1074/jbc.R110.125880

The Reaction Pathway
The biosynthesis of LTs is initiated by the action of 5-lipoxygenase (5-LOX), which promotes the transformation of
AA to LTA4. The action of 5-LOX is triggered by calcium-dependent membrane binding, which targets it to the nuclear
membrane. There it acquires its substrate, liberated from membrane phospholipids by the action of Ca2⫹-stimulated cytosolic
phospholipase A2, from the transmembrane protein FLAP
(five-lipoxygenase-activating protein). Like all LOXs, 5-LOX
catalyzes the regio- and stereospecific peroxidation of a polyunsaturated fatty acid (1, 2). The enzyme transforms the substrate AA to the 5S-isomer of hydroperoxyeicosatetraenoic
acid (5S-HPETE). However, in contrast to other members of
this superfamily, 5-LOX can further metabolize the hydroperoxy product to an allylic epoxide, specifically LTA4. Studies
have shown that both in vitro (3) and in vivo (4), the efficiency of
LTA4 production is improved with membrane binding, i.e.
5-LOX successfully carries the two-step reaction to completion, and the ratio of LTA4 to intermediate (5S-HPETE) produced is increased. (An alternative fate for 5S-HPETE is reduction to the corresponding hydroxyeicosatetraenoic acid.)
Subsequently, LTA4 is transformed to either LTB4 by the action
of LT hydrolase or LTC4 by the action of LTC4 synthase. The
former is a soluble enzyme that traffics between the nucleus and
cytoplasm, and the latter is a membrane-embedded enzyme
that is localized to the outer, but not inner, nuclear membrane
(Fig. 1).
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Leukotrienes (LTs), derived from arachidonic acid (AA)
released from the membrane by the action of phospholipase A2,
are potent lipid mediators of the inflammatory response. In
1983, Dahlén et al. demonstrated that LTC4, LTD4, and LTE4
mediate antigen-induced constriction of bronchi in tissue
obtained from subjects with asthma (Dahlén, S. E., Hansson, G.,
Hedqvist, P., Björck, T., Granström, E., and Dahlén, B. (1983)
Proc. Natl. Acad. Sci. U.S.A. 80, 1712–1716). Over the last 25ⴙ
years, substantial progress has been made in understanding how
LTs exert their effects, and a broader appreciation for the
numerous biological processes they mediate has emerged. LT
biosynthesis is initiated by the action of 5-lipoxygenase
(5-LOX), which catalyzes the transformation of AA to LTA4 in a
two-step reaction. Ca2ⴙ targets 5-LOX to the nuclear membrane, where it co-localizes with the 5-LOX-activating protein
FLAP and, when present, the downstream enzyme LTC4 synthase, both transmembrane proteins. Crystal structures of the
AA-metabolizing LOXs, LTC4 synthase, and FLAP combined
with biochemical data provide a framework for understanding
how subcellular organizations optimize the biosynthesis of
these labile hydrophobic signaling compounds, which must navigate pathways that include both membrane and soluble
enzymes. The insights these structures afford and the questions
they engender are discussed in this minireview.

The polyunsaturated fatty acid arachidonic acid (AA)2 serves
as a precursor to prostaglandins, leukotrienes (LTs), and other
eicosanoids derived from the 20-carbon substrate. The proteins
that constitute the LT biosynthetic pathway are located in several cellular compartments and include extra- and intracellular
as well as membrane and soluble proteins. Products of the
intracellular pathway are exported by specific pumps for further elaboration in extra- or transcellular biosynthesis or for
access to the extracellular receptors they target. The complex
compartmentalized biosynthetic pathway for LTs offers
numerous opportunities for control of pathway flux through
dynamic control of the locations of key proteins. We focus in

* This minireview will be reprinted in the 2010 Minireview Compendium,
which will be available in January, 2011.
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The abbreviations used are: AA, arachidonic acid; LT, leukotriene; 5-LOX,
5-lipoxygenase; 5S-HPETE, 5S-hydroperoxyeicosatetraenoic acid.
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Protein Structures
5-LOX—Although there is no structure available for 5-LOX,
structures for several plant (5– 8) and animal (9 –11) enzymes
(Fig. 2) have been determined. The LOX framework defined
by these structures contains two distinct domains. The first
of these is the smaller (⬃120 amino acids) PLAT (polycystin1/lipoxygenase/alpha-toxin) domain originally termed “C2like” because of its resemblance to the Ca2⫹-dependent C2
domains described in phospholipases and other Ca2⫹-dependent membrane-binding proteins such as synaptotagmin (12–
15). The structures of two PLAT domains that share Ca2⫹binding amino acids with 5-LOX (gangrene ␣-toxin (16, 17) and
8R-LOX from Plexaura homomalla (10)) revealed three Ca2⫹
ions positioned by the conserved amino acids. These structures
and a body of biochemical data suggest that 5-LOX similarly
harbors three Ca2⫹-binding sites in the N-terminal PLAT
domain. Mutation of the putative Ca2⫹-binding amino acids
abrogates membrane binding by 5-LOX (18 –21).
The remainder of the protein forms the catalytic domain
(⬃550 amino acids in animal enzymes and 750 in plant
enzymes); it is primarily ␣-helical and houses the catalytic iron.
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LOX fragment lacks the PLAT
domain and the first helix (␣1) and
loop of the catalytic domain, and in
this structure, ␣2 is not positioned
as it is in any intact LOX structure.
Furthermore, ␣2 crosses over the
site where the arched helix is found;
as a consequence, the arched helix is
also not properly positioned. (In
fact, the authors were unable to
model it in the electron density
map.) Because ␣1 makes no contacts with ␣2 in the full-length LOX
FIGURE 1. Initial events in LT biosynthesis. Ca2⫹ promotes membrane binding of both cytosolic phospho- structures, the structure of the trunlipase A2 (cPLA2; gray) and 5-LOX (salmon). The AA (see box) generated by phospholipase A2 is the substrate for
5-LOX. The 5-LOX product (LTA4) is converted to either LTC4 or LTB4 depending on the location of 5-LOX. *, OH cated LOX may indicate that ␣2 is
for the corresponding hydroxyeicosatetraenoic acid (5S-HETE), produced by reduction of 5S-HPETE. LTA4H, constrained by the N-terminal
LTA4 hydrolase; LTC4S, LTC4 synthase.
domain. In the absence of the physical restraint imposed by the PLAT
domain, neither ␣2 nor the arched helix is orientated correctly
in the 12S-LOX fragment.
As the substrate for animal LOXs is AA, the individual LOX
isoforms must discriminate among three chemically equivalent
methylene carbons to generate a single regio- and stereospecific product. Structures are available for rabbit reticulocyte
15-LOX (9, 26) and P. homomalla 8R-LOX (10, 11), enzymes
that have ⬃40% sequence identity to human 5-LOX. As one can
infer from the names, the former produces 15-HPETE (the
S-isomer) and the latter 8R-HPETE. These structures have led
to models for product specificity in the 15S- and 8R-enzymes,
but the product of 5-LOX represents a significant challenge to
extrapolation of these models. Experimental results are consistent with a mechanism that requires abstraction of hydrogen at
the central carbon of a pentadiene, followed by the antarafacial
FIGURE 2. 8R-LOX. The schematic shows 8R-LOX from P. homomalla (Protein peroxidation of the free radical intermediate, i.e. hydrogen
Data Bank code 2FNQ). The membrane-targeting PLAT domain is in purple,
abstraction and oxygenation must occur on opposite sides of
and the catalytic domain is in white. Blue spheres mark the Ca2⫹ ions positioned by amino acids conserved in 5-LOX, which are included in stick render- the pentadiene (for review, see Ref. 28). The site of peroxidation
ing. White, carbon; red, oxygen; blue, nitrogen. Trp residues in the PLAT is either C⫹2 or C⫺2 relative to the position of hydrogen
domain found in the putative membrane insertion loops common to 8R- and
5-LOXs are show as gold spheres. The catalytic iron is shown as an orange abstraction. For the models inferred from the rabbit and coral
sphere, and the position of the terminal amino acid is in red. The arched helix, structures that explain the products of these enzymes, the stewhich shelters the active site, is in green.
reochemistry of the product is consistent with the carboxylate
of the AA tethered by surface amino acids (carboxylate out).
The iron is positioned by both side and main chain contacts: However, the stereochemistry of the 5-LOX product and the
conserved histidines fill the coordination sphere as well as the fact that peroxidation occurs on the opposite side of the submain chain carboxylate of the C terminus. Another structurally strate to hydrogen abstraction necessitate an inverse orientadistinct conserved feature in this domain, previously described tion of substrate (carboxylate in). Furthermore, the consecutive
in detail by Minor et al. (6) for soybean LOX L-1, is an arched reactions catalyzed by 5-LOX require hydrogen abstraction
helix that shields access to the catalytic iron. The curvature from two of the three pentadienes in the substrate (attack at C7
of the helix is a consequence of a reverse-turn insertion that and C10). The 8R- and 15-LOXs perform abstraction at C10
contains an invariant glycine. Just prior to the reverse turn is and C13, respectively. Thus, despite compelling experimental
an invariant Leu that has been proposed to control access of O2 data testing a model for 5-LOX product specificity (e.g. Ref. 29),
to the substrate (22, 23) and to position the substrate penta- in the absence of a structure of 5-LOX or other LOX with
diene for attack (11). The PLAT and catalytic domains appear “inverse entry,” it is difficult to predict with certainty the structo constitute independently folded domains, and there are tural basis for 5-LOX specificity.
FLAP and LTC4 Synthase—Targeted to the membrane by
reports of LOX truncations (lacking the N-terminal domain)
that are catalytically active (24, 25). However, the structure of a the binding of Ca2⫹, 5-LOX is localized to the nuclear memtruncated form of 12S-LOX (Protein Data Bank code 3D3L) brane, where both its “helper” protein FLAP (Fig. 3) and LTC4
suggests that the PLAT domain may critically influence the synthase, an enzyme that metabolizes the 5-LOX product, can
three-dimensional structure of the catalytic domain. The 12S- be found. The two proteins, which span the bilayer, are mem-
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FIGURE 4. LTA4 hydrolase. a, thermolysin-like (M1 peptidase) core of LTA4
hydrolase. Zn2⫹ is a gray sphere. b, LTA4 hydrolase (Protein Data Bank code
1HS6). Purple, N-terminal domain; green, C-terminal domain. The arrow marks
the approximate position of the active-site access channel.

FIGURE 3. FLAP and LTC4 synthase. a, schematic of a FLAP trimer (Protein
Data Bank code 2Q7M). Monomers are in purple, blue, and pink. The inhibitor
MK-591 is depicted in stick rendering. Yellow, carbon; red, oxygen; blue, nitrogen. b, superposition of a LTC4 synthase monomer (beige; code 2UUH) onto
FLAP. GSH is in sphere rendering. Magenta, carbon; orange, sulfur. The stick
rendering corresponds to a detergent molecule and is presumed to indicate
the binding site for LTA4.

bers of the MAPEG (membrane-associated proteins in eicosanoid and glutathione metabolism) superfamily (30, 31). Crystal structures have been obtained for both (32–34), with that of
LTC4 synthase at significantly higher resolution (2.15 Å (33)
versus 4.0 Å (34) resolution). The proteins are trimers of fourhelix bundles with active sites located at monomer interfaces.
FLAP appears to represent a distinct subclass in the family, as
unlike the other MAPEG family members, it does not have a
catalytic activity or a binding site for GSH. All other MAPEG
proteins either conjugate GSH with their substrate or metabolize GSH in the catalytic cycle. Furthermore, a structure-based
sequence lineup of MAPEG proteins supports the premise that
FLAP represents a unique subclass (35), and FLAP homologs
from Danio rerio to Homo sapiens show specific hallmarks: distinct loop sequences that connect helices ␣1 and ␣2 and helices
␣3 and ␣4. These are the loops at the surface of the membrane,
i.e. the regions of the protein most likely to interact with 5-LOX
should a specific protein-protein interaction occur. A role in a
specific interaction with a protein partner is consistent with the
fact that the sequences of the surface loops of FLAP are highly
conserved. In Fig. 3, the structure of a monomer of LTC4 synthase with the GSH co-substrate is superimposed on that of
FLAP. In this orientation, it is clear that the N-terminal portion
of FLAP helix ␣4 is “unwound” compared with the GSH-dependent MAPEG structures. The resulting extended loop region
blocks access to the GSH-binding site region of the glutathionedependent MAPEG proteins. Moreover, FLAP also lacks the
conserved side chains that interact with GSH.
The structure of LTC4 synthase, which catalyzes the conjugation of GSH to LTA4, includes GSH, and the FLAP structure
includes the competitive inhibitor of AA binding MK-591. Both
ligands are located in a groove formed by helices ␣1 and ␣4
from neighboring protomers. Furthermore, both proteins have
all three sites in the trimers occupied. The GSH subsite of the
synthase is in a deeper portion of the groove, and LTA4 is
thought to occupy the region of the site that contains a cocrystallized detergent molecule. This arrangement makes the
AUGUST 13, 2010 • VOLUME 285 • NUMBER 33

LTA4 subsite more superficial with respect to the protein than
the GSH subsite. However, the LT subsite extends along the
surface of protein and penetrates deep into the membrane
bilayer. The arrangement of the LTA4 and GSH subsites, with
the GSH buried deeper in the protein, led to the suggestion that
GSH binds first and induces a conformation that is amenable to
LTA4 binding (33). However, previous kinetic data for this and
other MAPEG proteins are consistent with a random binding
order (36). In contrast, FLAP has a single binding cavity in the
groove between monomers. In the x-ray structure of FLAP, the
competitive inhibitor of AA is found in the region of the protein
buried in the bilayer. Thus, the locations of the AA- and LTA4binding sites in FLAP and LTC4 synthase deep in the bilayer are
consistent with a model in which the proteins obtain their
ligand/substrate directly from the bilayer by lateral diffusion.
LTA4 Hydrolase—The product of the 5-LOX reaction is also
the substrate for LTA4 hydrolase. This soluble enzyme converts
LTA4 into LTB4 and thus provides an alternative fate for the
product of the 5-LOX reaction. The crystal structure of LTA4
hydrolase confirmed the prediction from sequence alignments
that it is a member of the M1 amino peptidase superfamily (37,
38). These are zinc-containing amino peptidases typified by
thermolysin. However, LTA4 hydrolase is roughly double the
size of thermolysin, as it contains two additional domains: an
all-␤-domain at the N terminus and an ␣-helical domain at the
C terminus (Fig. 4). These two domains extend from the thermolysin-like core to close over what would be the exposed peptide-binding site in an M1 peptidase. The triangular arrangement of the three domains allows access to the catalytic zinc via
a central channel. In addition to the hydrolase activity, the
enzyme also has peptidase activity, but a biological role for the
peptidase activity remains to be identified. It is interesting to
note that the LTA4 hydrolase-“modified” M1 peptidase structure is not unique to an enzyme of the LT biosynthetic pathway.
A similar structure has been described for a cold-active amino
peptidase from Colwellia psychrerythraea (39).

Compartmentalization
What Determines the Fate of the 5-LOX Product?—Clustering of sequential catalytic activities is thought to provide a
mechanism to enhance biosynthetic efficiency, and reversible
clustering of six enzymes in the de novo biosynthetic pathway
for purines has been shown to occur in the cytoplasm in
response to changes in purine levels (40). The proteins of the LT
JOURNAL OF BIOLOGICAL CHEMISTRY

25111

MINIREVIEW: Compartmentalization in Leukotriene Biosynthesis
biosynthetic pathway are found in the nucleus, cytoplasm,
inner and outer nuclear membranes, and extracellular space
and, as a result, are not free to reversibly cluster. In addition,
some steps in the pathway that further modify the LTs are transcellular (e.g. Ref. 41). Consequently, regulation of pathway flux
can be executed by the subcellular targeting of key enzymes. For
example, as described below, targeting of 5-LOX to the outer
nuclear membrane is thought to promote the formation of the
cysteinyl-LTs, whereas 5-LOX targeting to the inner nuclear
membrane results in the production of LTB4 (37, 38).
The LTC4 synthase and LTA4 hydrolase activities represent a bifurcation of the LT biosynthetic pathway: the former
directs the 5-LOX product into the production of cysteinylLTs such as LTC4 and LTD4 and the latter to LTB4. These
LTs are distinct in the biological responses they trigger; thus, an
intriguing aspect of the regulation of LT biosynthesis is how the
relative rates of cysteinyl-LT and LTB4 production are controlled. Compartmentalization of enzyme activities has been
proposed to play a significant role in the regulation of LT production. Prior to activation, 5-LOX can reside in the cytoplasm
or the nucleus (due to the presence of multiple nuclear location
sequences (42, 43)); furthermore, its cellular location is
dynamic and can vary with cell type. One mechanism of control
of 5-LOX location is phosphorylation. For instance, phosphorylation of Ser-271 interferes with the export of 5-LOX from the
nucleus (44). Thus, cell stimulation results in the Ca2⫹-dependent targeting of 5-LOX to the inner and/or outer nuclear
membrane(s), depending upon the compartment(s) in which
the unstimulated enzyme resides.
Recall that 5-LOX is presented its substrate by its helper protein FLAP, located in the nuclear membrane. Although FLAP is
not required for 5-LOX activity or its translocation to the membrane, in vivo, the cellular capacity for LT synthesis correlates
with FLAP expression (45– 47). Furthermore, inhibitors of
FLAP are effective inhibitors of LT production (48). MK-591,
the drug with which FLAP was crystallized, inhibits LT biosynthesis through binding to FLAP. Recall also that LTC4 synthase
is a structurally similar membrane protein. However, in contrast to FLAP, which is distributed on both the inner and outer
nuclear membranes, LTC4 synthase is restricted to the outer
nuclear membrane (49). Studies by Mandal et al. (50) revealed
two populations of FLAP in the nuclear membrane: FLAP that
is unassociated and FLAP that is associated with LTC4 synthase. Because FLAP is more abundant than LTC4 synthase,
there is no LTC4 synthase that is not in complex with FLAP.
The authors proposed the existence of two pools of FLAP,
one to channel LTA4 to the synthase and the other to allow
access to the LT by LTA4 hydrolase. In subsequent work, the
authors demonstrated activation-dependent assembly of a
complex of 5-LOX and FLAP (51). In their model, the outer
nuclear membrane complex is composed of 5-LOX, FLAP, and
LTC4 synthase, whereas on the inner membrane, which is
devoid of the synthase, the complex consists of 5-LOX and
FLAP. Interaction of FLAP with both LTC4 synthase and
5-LOX has been suggested by others (52).
Implications for Substrate Transfer—The proposed AAbinding site in FLAP is deep within the hydrophobic region
of the bilayer. This placement appears to preclude a direct
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interaction between the donor- and acceptor-binding sites
and suggests that accessibility to FLAP-bound AA by 5-LOX
is limited, even when the enzyme is membrane-bound. The
only part of 5-LOX demonstrated to penetrate the bilayer is
the putative membrane insertion loop that contains Trp-75 in
the PLAT domain. This amino acid has been proposed to insert
⬃9 Å deep into the bilayer (53). Thus, 5-LOX is tethered to the
membrane with calcium activation, but its substrate is bound
deep within the hydrophobic bilayer to the helper protein
FLAP. How the AA travels from its position in the bilayer to the
catalytic domain of LOX, which does not localize to the membrane in the absence a functional PLAT domain, is unknown.
Note from Fig. 2 that the overall structure of LOX is an elongated ellipsoid. The membrane-tethering PLAT domain
encompasses the first third of the ellipsoid, and the catalytic
domain encompasses the remaining two-thirds. The entrance
to the active site is roughly in the middle of the catalytic
domain, ⬃30 Å removed from the PLAT-catalytic domain
interface. Thus, direct passage of substrate from the bilayer to
the active site of the soluble enzyme (as occurs in some monotypic membrane-associated enzymes (54)) can occur only if the
catalytic domain abuts the membrane. A green fluorescent protein-labeled catalytic domain-only construct does not translocate to the nuclear membrane under conditions that mobilize
the similarly tagged PLAT domain (18). However, this observation does not rule out an association of the catalytic domain
with the membrane once it is tethered by the PLAT domain.
Another aspect of substrate transfer to consider is the orientation of AA in FLAP. The structures of both FLAP and LTC4
synthase suggest that AA and LTA4 bind with the hydrophobic
tails innermost in the membrane and the carboxylate groups at
the membrane surface. This may require that the initial interaction of 5-LOX with FLAP-bound AA is via the substrate carboxylate. Such a transfer mechanism might utilize a positively
charged amino acid at the entrance to the active site.
LTA4 hydrolase, the alternative enzyme that metabolizes
LTA4, is a soluble enzyme found in the nucleus and cytoplasm
(55). Its distribution between these compartments is dynamic
(56). Luo et al. (57) have shown that the cellular capacity for the
synthesis of LTB4 correlates with the capacity for import of
5-LOX into the nucleus. Thus, the exclusion of LTC4 synthase
from the inner nuclear membrane and the presence of the
hydrolase in the nucleus result in a pool of LTA4 that does not
have access to the cysteinyl-LT biosynthetic branch of the
bifurcation but is available to the hydrolase. If LTC4 were not
excluded from the inner nuclear membrane in cells expressing
both LTC4 synthase and LTA4 hydrolase, the transmembrane
synthase would have preferential access to substrate due to its
proximity to FLAP and consequently 5-LOX. The clustering of
FLAP, 5-LOX, and LTC4 synthase is likely to maximize the
partitioning of the hydrophobic LTA4 in the membrane phase.
The half-life of LTA4 is ⬃10 s in aqueous milieu but is significantly extended in the presence of phospholipids (58). As a
consequence, even the chemical nature of the phospholipid
bilayer favors the LTC4 synthase reaction over that of the
hydrolase, as the substrate need not enter an aqueous environment, where it is susceptible to non-enzymatic hydrolysis.
VOLUME 285 • NUMBER 33 • AUGUST 13, 2010
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The bifurcation of the LT biosynthetic pathway after the production of LTA4 contributes to the production of LTs of diverse
structures and functions. However, data suggest that downstream events in one pathway branch can have an effect on the
flux through the alternative branch. LTC4 is exported from the
cell by the membrane pump known as MRP1 (multidrug resistance protein-1); in mice lacking the multidrug export pump,
LTB4 synthesis is increased. The interpretation of this result is
that LTC4 accumulation inhibits LTC4 synthase activity, and
thus, more LTA4 is available for metabolism by the hydrolase
(59).
Concluding Remarks —The initial step in LT synthesis is catalyzed by the Ca2⫹-dependent membrane-binding enzyme
5-LOX. 5-LOX is translocated to the nuclear membrane, and
whether it is located on the inner or outer nuclear membrane
appears to determine the fate of its product, LTA4. Thus, at an
early step in LT biosynthesis, compartmentalization is an
important determinant in pathway flux within the branches of
this intricate biosynthetic pathway for lipid mediators. Furthermore, compartmentalization can be regulated by post-translational modifications such as phosphorylation. Downstream
enzymes and proteins in the pathway reside in multiple cellular
compartments; thus, it is likely that a regulatory mechanism
that requires mobility of a key enzyme is repeated farther down
the line. An issue that was only briefly alluded to here but is
likely to impact LT production is the lability of pathway intermediates. For example, LTA4 is subject to non-enzymatic
hydrolysis, but the half-life in the cell can be extended by either
its association with phospholipid membrane (58) or fatty acidbinding proteins (27, 60). Thus, on top of spatial restraints
imposed by the multiple compartments occupied by LT biosynthetic enzymes are temporal constraints that further impact
pathway flux. The abundance of structural and functional data
on early events in LT biosynthesis helps simplify our perception
of the complex pathway for LT biosynthesis.
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